Japan Food Tech Holdings, Inc.

What they do

Japan Food Tech Holdings operates through its wholly owned subsidiary Dr. Foods Co., Ltd. in Japan, with a second subsidiary, Dr. Foods (S) PTE. LTD. in Singapore, which has no material operations. The company currently resells plant-based food products manufactured by Mama Foods Co., Ltd., including 'Dr. Foie Gras', a vegan foie gras alternative made from fermented nuts and beans. They are also researching and developing other plant-based products such as vegan caviar, cultured caviar, and vegan truffle butter, with development and production support from Mama Foods.

Revenue drivers

• Dr. Foie Gras — The only product currently sold, generating $15,922 in revenue for fiscal year 2024. It is resold to customers in Japan, sourced from Mama Foods Co., Ltd.
• Next Kalbi Chips development — Collaborative development effort with Next Meats Co., Ltd. for a short-rib style alternative meat product, but the company states it will not generate revenue from this arrangement unless it acquires Mama Foods, which is speculative.

Recent performance

For the fiscal year ended March 31, 2024, the company reported revenue of $15,922, a significant increase from $1,038 in the prior year, but a net loss of $761,837, up from a net loss of $321,820 in fiscal 2023. Cash used in operations was $256,940 for fiscal 2024. As of June 30, 2024, total assets were $17,324, total liabilities were $49,347, and shareholder equity was negative $32,023. Quarterly revenue has fluctuated, with $5,276 in the quarter ended June 30, 2024.

Strategy

Management's stated focus is on creating plant-based food products that replace traditional animal products while retaining taste and texture. The company plans to rely on Next Meats Holdings, Inc. to promote Dr. Foie Gras, with compensation on a case-by-case basis, and currently has no formal marketing plan. Funding for operations is expected to come from loans or capital contributions from CEO Koichi Ishizuka or White Knight Co., Ltd., as well as potential sales of common stock. The company has filed a patent application in Japan for its production method for Dr. Foie Gras.

Risks

• Insufficient capital — The company states its cash balance is not sufficient to fund operations and revenues are not sufficient to cover costs, requiring additional funding to continue operations for the next twelve months.
• Related party concentration — Mama Foods, the sole manufacturer of its products, is controlled by CEO Koichi Ishizuka, and Next Meats, which will handle marketing, is also controlled by him, creating significant related party dependencies.
• No formal funding agreements — There is no formal agreement with CEO Ishizuka or White Knight to provide loans or advances, so funding is not assured.
• Nominal sales and no marketing plan — Sales have been nominal due to limited market exposure and no marketing plan, and the company cannot forecast when or if global expansion will be feasible.

Outlook

Management expects to require additional funding within the next twelve months to implement its plan of operations, but has no arrangements for such financing. If additional cash cannot be raised, operations may be suspended or ceased entirely. The company is focused on bringing new plant-based products to market, but cannot predict when these will generate revenue.